Price
No data yet.
Social Signal Score
Revenue
$9.04M-2.07%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Arthur T. Sands
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 317
- Beta
- 1.80
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 8.04
Financials
Revenue
$9.04M-2.1%Net Income
$-89.53MEBITDA
$-85.96MFree Cash Flow
$-98.51MEPS (diluted)
$-0.81Shares Outstanding (diluted)
111.08M+3433.5%Operating Expenses
$103.25MCash & Debt
$443.53MReturn of Capital
$0.00Revenue by Segment (annual)
$83.98MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $83.98M | $-264.46M | $-3.05 |
| 2024 | $54.55M | $-193.57M | $-2.88 |
| 2023 | $76.99M | $-143.95M | $-2.65 |
| 2022 | $38.63M | $-180.36M | $-3.71 |
| 2021 | $29.75M | $-117.19M | $-2.73 |
| 2020 | $17.82M | $-43.24M | $-2.76 |
| 2019 | $31.11M | $-21.70M | $-0.56 |
| 2018 | $37.45M | $-9.43M | $-0.59 |
Valuation
NRIXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120-5.26%Social Signal Score
Mentions (2)
- Newsseekingalpha.com·5h ago·Positive
Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·1d ago·Positive
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why Nurix Therapeutics (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗
Earnings
Thu, Oct 8(in 4 weeks)
Consensus estimate $-0.60 per share
Typical surprise -3.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 9$-0.81 vs $-0.72miss
- Wed, Apr 8$-0.79 vs $-0.76miss
- Wed, Jan 28$-0.82 vs $-0.84beat
- Thu, Oct 9$-1.03 vs $-0.84miss
- Wed, Jul 9$-0.52 vs $-0.71beat
- Tue, Apr 8$-0.67 vs $-0.72beat
Estimates and results for NRIX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NRIX officers and directors.
- Bought
- —
- Sold
- $3.4m
0 trades
27 trades
- Ring Christinesold
- Ring Christinesold
- Hansen Gwennsold
- Hansen Gwennsold
- Hansen Gwennsold
- Hansen Gwennsold
- Van Houte Hanssold
- Van Houte Hanssold
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NRIX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.